An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

Written by Jonathan Ponciano for The Motley Fool

Karen Prange disposed of 3,564 shares for a total transaction value of approximately $138,283 on August 5.

The sale resulted in a 14% reduction in the director's total direct equity holdings in the company.

All transacted shares were held directly; the director reported no indirect holdings in the filing.

Karen Prange, a director of the company, sold 23,325 shares of common stock in AtriCure, Inc. (NASDAQ:ATRC) on August 5, according to an SEC Form 4 filing.

Transaction value based on SEC Form 4 weighted average sale price ($38.80); post-transaction value based on August 5 market close ($39.34).

AtriCure is a focused medical device company with a $2.0 billion market capitalization and $569.6 million in TTM revenue, positioning itself as a specialized provider of cardiac surgical solutions. The company maintains a differentiated product portfolio centered on radiofrequency ablation technology, which provides competitive advantages in the treatment of cardiac arrhythmias and related conditions. With a global distribution network spanning multiple continents, AtriCure has established itself as a significant player in the cardiac surgery device market.

A director cutting 14% of their common stock holdings in one sale is a bit more than the usual haircut, but the timing takes some of the edge off, landing roughly two weeks after earnings, with shares well above a $25 price in June but just below where the stock closed the day of the transaction. Prange sold in the open market rather than to cover taxes, which makes it a genuine choice, but she kept nearly 23,000 shares, so ultimately, this reads as a director trimming after a strong report rather than heading for the door.That report marked a real turn for the business. AtriCure grew second-quarter revenue 13% to $154 million and swung to $9 million in net income from a loss a year earlier, with its pain management franchise up 27% on adoption of its cryoSPHERE MAX probe. CEO Michael Carrel said the company "delivered solid second quarter results,” and management raised full-year revenue and profit guidance on the strength of it. For long-term holders, that profitability is important to watch because AtriCure spent years growing sales without consistent earnings, and a quarter that pairs the two matters more than one director trimming her position.

Before you buy stock in AtriCure, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AtriCure wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $397,405!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,344,091!*

Now, it’s worth noting Stock Advisor’s total average return is 953% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

*Stock Advisor returns as of August 7, 2026.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.